China's second Anti Japanese war won the priority review! Market acceleration of Amgen heavy duty leukemia drugs

On December 9, 2019, Amgen's import listing application of blincyto (bilintomolobin for injection) was publicized by CDE priority review, and is expected to be approved for listing quickly! Blincyto is the first bite in the world Immunotherapy, developed by Amgen company, combines CD19 antigen expressed on the surface of B cells at one end and CD3 receptor on the surface of T cells at the other end, which can collect T cells near cancer cells and promote their killing on cancer cells Blincyto was approved for the first time in the world in December 2014 At present, it has been approved for the treatment of relapsed / refractory B-cell all patients It is the first FDA approved drug to destroy leukemia cells through human T cells According to the drug intelligence data, on October 29, this bispecific antibody heavyweight drug submitted an application for listing in China, acceptance No.: jxss1900060 On November 1, Amgen, an American biopharmaceutical giant, announced the purchase of 20.5% of the equity of China's high-profile innovative biopharmaceutical enterprise Baiji Shenzhou, and the two sides reached a global strategic cooperation relationship on cancer The cooperation content includes blincyto for injection Today (December 9), the official CDE website showed that: the application for the listing of bilintomolide for injection was publicized by the CDE priority review At present, there is only one bispecific antibody for injection of emcezumab under Roche in China It is reported that in 2018, the global sales of bellintomolobib was US $230 million, and the global sales of emacezumab was CHF 234 million This time, the company applies for import in China and will become the second approved bispecific antibody in China through the priority approval channel, which will bring great benefits to the patients with blood cancer in China Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.